Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink
09:40am, Tuesday, 25'th Oct 2022 The Motley Fool
You may have to take a shot on some riskier plays if you want to make up your portfolio's significant loss of yardage.
Scancell signs exclusive deal with Genmab for anti-glycan antitbody
03:35am, Tuesday, 25'th Oct 2022
Scancell has signed a deal worth up to US$208mln in upfront and milestone payments to license its anti-glycan antibody to cancer therapy specialist Genmab (CSE:GEN). A US$24bn Nasdaq-listed Danish gro
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
01:11pm, Friday, 21'st Oct 2022 Zacks Investment Research
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
10:32am, Friday, 21'st Oct 2022
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
04:06pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.
INCY vs. GMAB: Which Stock Is the Better Value Option?
03:40pm, Monday, 17'th Oct 2022 Zacks Investment Research
INCY vs. GMAB: Which Stock Is the Better Value Option?
INCY vs. GMAB: Which Stock Is the Better Value Option?
12:48pm, Monday, 17'th Oct 2022
INCY vs. GMAB: Which Stock Is the Better Value Option?
Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates?
04:31pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
UnitedHealth Group's (UNH) third-quarter results are likely to benefit from higher premiums and membership growth in its UnitedHealthcare unit, partly offset by elevated technology investment costs.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock
07:39pm, Monday, 22'nd Aug 2022 Benzinga
HC Wainwright increased the price target on Genmab A/S (NASDAQ: GMAB) from $49 to $51, with a Buy rating.
The analyst cites that Genmab recorded a Q2 diluted net income of DKK28.66 per share, bett
Where Genmab Stands With Analysts
12:17pm, Thursday, 11'th Aug 2022 Benzinga
Genmab (NASDAQ:GMAB) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
2
1
0
Last 30D
0
0
Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript
02:30am, Thursday, 11'th Aug 2022 The Motley Fool
GMAB earnings call for the period ending June 30, 2022.
Genmab A/S (GMAB) CEO Jan van de Winkel on Q2 2022 Results - Earnings Call Transcript
05:48pm, Wednesday, 10'th Aug 2022
Genmab A/S (GMAB) Q2 2022 Results Conference Call August 10, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Offic
Genmab: A Royalty Powerhouse With A Strong Pipeline
10:26am, Tuesday, 28'th Jun 2022
Genmab is receiving substantial and growing royalties from big pharma partners. The royalties are helping the company build its pipeline and to establish its own commercial infrastructure.
Genmab: Looking For Growth At A Reasonable Price
11:55pm, Thursday, 09'th Jun 2022
Genmab is one of my top picks in healthcare. The company expects to report impressive growth over the remainder of 2022 and beyond. Genmab has an imposing pipeline of proprietary and partnered program
